Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: CORRECTION - Re: Agora----So let me get this straight, we can dec 11th 2009

Sorry AGORACOM...IMHO, to "clarify" that statement is not accompllished by just eliminating it.

There was either a further explanation needed that states.... the eliminated words are not in any way related to a current, possible buyout of the MMP, PTSG, PTSC or even a buyout of Mr. Moore's or TPL's portion of their interest in our investment...or...a PR from someone, PTSC, TPL whomever, making what information there may be concerning such an event now public knowledge.

If Agoracom was in complete error in including that statement regarding a buyout then say so...say it was an error with no such knowledge being available to you....if not..then rule 100 of the FD Regs states...and someone should comply...

Rule 100 of Regulation FD sets forth the basic rule regarding selective disclosure. Under this rule, whenever:

    (a) simultaneously (for intentional disclosures), or

    (b) promptly (for non-intentional disclosures).

(1) an issuer, or person acting on its behalf,

(2) discloses material nonpublic information,

(3) to certain enumerated persons (in general, securities market professionals or holders of the issuer's securities who may well trade on the basis of the information),

(4) the issuer must make public disclosure of that same information:

As a whole, the regulation requires that when an issuer makes an intentional disclosure of material nonpublic information to a person covered by the regulation, it must do so in a manner that provides general public disclosure, rather than through a selective disclosure. For a selective disclosure that is non-intentional, the issuer must publicly disclose the information promptly after it knows (or is reckless in not knowing) that the information selectively disclosed was both material and nonpublic.

Share
New Message
Please login to post a reply